Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A
Identifieur interne : 004A01 ( Main/Exploration ); précédent : 004A00; suivant : 004A02Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A
Auteurs : Allison Brashear [États-Unis] ; Kathleen Bergan [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Eric R. Siemers [États-Unis] ; Walter Ambrosius [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-01.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Adverse Drug Reaction Reporting Systems, Aged, Bontoxilysin, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Botulinum toxin, Botulism, Cervical dystonia, Chemotherapy, Dose, Dystonia, Evolution, Female, Human, Humans, Injections, Intramuscular, Long term, Male, Middle Aged, Muscle relaxant, Patient, Patient Dropouts, Patient Satisfaction, Perception, Torticollis, Torticollis (drug therapy), Toxin, Treatment, Treatment Outcome, Treatment withdrawal.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- chemical , adverse effects : Botulinum Toxins, Type A.
- drug therapy : Torticollis.
- Adult, Adverse Drug Reaction Reporting Systems, Aged, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Patient Dropouts, Patient Satisfaction, Treatment Outcome.
Abstract
Despite widespread commercial acceptance of botulinum toxin (BTX) for idiopathic cervical dystonia (ICD), no follow up has been performed to determine when and why some patients stop therapy. It has been suggested that some patients who stop BTX treatment may do so because of permanent improvement.1 We surveyed 155 patients with ICD who were treated over 6 years with BTX to determine when and why patients stopped treatment with BTX, and what adverse events and changes in dose and/or frequency of treatments occurred in those who continued treatment. Of the 133 (86.6%) individuals returning the surveys, 104 continued on BTX treatment and 29 had stopped therapy. Of the 29 subjects no longer receiving BTX, 11 individuals had only received one or two injections. Prior surgical treatment for ICD did not influence their decision to stop therapy. Of those 104 of 133 continuing on BTX treatments, two thirds of the subjects reported the injections always help, whereas one quarter estimated one set of injections did not help. One third of those continuing treatment reported the first injection was most helpful, whereas another one third felt all injections were similarly effective. After an initial adjustment, BTX dosages and frequency of treatment remained stable in this group.
Url:
DOI: 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002703
- to stream Istex, to step Curation: 002703
- to stream Istex, to step Checkpoint: 003201
- to stream Main, to step Merge: 007298
- to stream PascalFrancis, to step Corpus: 002C61
- to stream PascalFrancis, to step Curation: 000060
- to stream PascalFrancis, to step Checkpoint: 002B47
- to stream Main, to step Merge: 007539
- to stream PubMed, to step Corpus: 004047
- to stream PubMed, to step Curation: 004047
- to stream PubMed, to step Checkpoint: 003F13
- to stream Ncbi, to step Merge: 000204
- to stream Ncbi, to step Curation: 000204
- to stream Ncbi, to step Checkpoint: 000204
- to stream Main, to step Merge: 007056
- to stream Main, to step Curation: 004A01
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A</title><author><name sortKey="Brashear, Allison" sort="Brashear, Allison" uniqKey="Brashear A" first="Allison" last="Brashear">Allison Brashear</name></author><author><name sortKey="Bergan, Kathleen" sort="Bergan, Kathleen" uniqKey="Bergan K" first="Kathleen" last="Bergan">Kathleen Bergan</name></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name></author><author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name></author><author><name sortKey="Ambrosius, Walter" sort="Ambrosius, Walter" uniqKey="Ambrosius W" first="Walter" last="Ambrosius">Walter Ambrosius</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:43C497DDCA5A507072311135BEDC7E711CEBCB44</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X</idno><idno type="url">https://api.istex.fr/document/43C497DDCA5A507072311135BEDC7E711CEBCB44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002703</idno><idno type="wicri:Area/Istex/Curation">002703</idno><idno type="wicri:Area/Istex/Checkpoint">003201</idno><idno type="wicri:doubleKey">0885-3185:2000:Brashear A:patients:perception:of</idno><idno type="wicri:Area/Main/Merge">007298</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:00-0067098</idno><idno type="wicri:Area/PascalFrancis/Corpus">002C61</idno><idno type="wicri:Area/PascalFrancis/Curation">000060</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002B47</idno><idno type="wicri:doubleKey">0885-3185:2000:Brashear A:patients:perception:of</idno><idno type="wicri:Area/Main/Merge">007539</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10634256</idno><idno type="wicri:Area/PubMed/Corpus">004047</idno><idno type="wicri:Area/PubMed/Curation">004047</idno><idno type="wicri:Area/PubMed/Checkpoint">003F13</idno><idno type="wicri:Area/Ncbi/Merge">000204</idno><idno type="wicri:Area/Ncbi/Curation">000204</idno><idno type="wicri:Area/Ncbi/Checkpoint">000204</idno><idno type="wicri:doubleKey">0885-3185:2000:Brashear A:patients:perception:of</idno><idno type="wicri:Area/Main/Merge">007056</idno><idno type="wicri:Area/Main/Curation">004A01</idno><idno type="wicri:Area/Main/Exploration">004A01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A</title><author><name sortKey="Brashear, Allison" sort="Brashear, Allison" uniqKey="Brashear A" first="Allison" last="Brashear">Allison Brashear</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Bergan, Kathleen" sort="Bergan, Kathleen" uniqKey="Bergan K" first="Kathleen" last="Bergan">Kathleen Bergan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Ambrosius, Walter" sort="Ambrosius, Walter" uniqKey="Ambrosius W" first="Walter" last="Ambrosius">Walter Ambrosius</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-01">2000-01</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="150">150</biblScope><biblScope unit="page" to="153">153</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">43C497DDCA5A507072311135BEDC7E711CEBCB44</idno><idno type="DOI">10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X</idno><idno type="ArticleID">MDS1024</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Adverse Drug Reaction Reporting Systems</term><term>Aged</term><term>Bontoxilysin</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (adverse effects)</term><term>Botulinum toxin</term><term>Botulism</term><term>Cervical dystonia</term><term>Chemotherapy</term><term>Dose</term><term>Dystonia</term><term>Evolution</term><term>Female</term><term>Human</term><term>Humans</term><term>Injections, Intramuscular</term><term>Long term</term><term>Male</term><term>Middle Aged</term><term>Muscle relaxant</term><term>Patient</term><term>Patient Dropouts</term><term>Patient Satisfaction</term><term>Perception</term><term>Torticollis</term><term>Torticollis (drug therapy)</term><term>Toxin</term><term>Treatment</term><term>Treatment Outcome</term><term>Treatment withdrawal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Adverse Drug Reaction Reporting Systems</term><term>Aged</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Patient Dropouts</term><term>Patient Satisfaction</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Arrêt traitement</term><term>Bontoxilysin</term><term>Botulisme</term><term>Chimiothérapie</term><term>Dose</term><term>Dystonie</term><term>Evolution</term><term>Homme</term><term>Long terme</term><term>Malade</term><term>Myorésolutif</term><term>Perception</term><term>Torticolis</term><term>Toxine</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite widespread commercial acceptance of botulinum toxin (BTX) for idiopathic cervical dystonia (ICD), no follow up has been performed to determine when and why some patients stop therapy. It has been suggested that some patients who stop BTX treatment may do so because of permanent improvement.1 We surveyed 155 patients with ICD who were treated over 6 years with BTX to determine when and why patients stopped treatment with BTX, and what adverse events and changes in dose and/or frequency of treatments occurred in those who continued treatment. Of the 133 (86.6%) individuals returning the surveys, 104 continued on BTX treatment and 29 had stopped therapy. Of the 29 subjects no longer receiving BTX, 11 individuals had only received one or two injections. Prior surgical treatment for ICD did not influence their decision to stop therapy. Of those 104 of 133 continuing on BTX treatments, two thirds of the subjects reported the injections always help, whereas one quarter estimated one set of injections did not help. One third of those continuing treatment reported the first injection was most helpful, whereas another one third felt all injections were similarly effective. After an initial adjustment, BTX dosages and frequency of treatment remained stable in this group.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Indiana</li></region></list><tree><country name="États-Unis"><region name="Indiana"><name sortKey="Brashear, Allison" sort="Brashear, Allison" uniqKey="Brashear A" first="Allison" last="Brashear">Allison Brashear</name></region><name sortKey="Ambrosius, Walter" sort="Ambrosius, Walter" uniqKey="Ambrosius W" first="Walter" last="Ambrosius">Walter Ambrosius</name><name sortKey="Bergan, Kathleen" sort="Bergan, Kathleen" uniqKey="Bergan K" first="Kathleen" last="Bergan">Kathleen Bergan</name><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:43C497DDCA5A507072311135BEDC7E711CEBCB44
|texte= Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A
}}
| This area was generated with Dilib version V0.6.23. |  |